MX2018011202A - Vesiculas de membrana terapeuticas. - Google Patents

Vesiculas de membrana terapeuticas.

Info

Publication number
MX2018011202A
MX2018011202A MX2018011202A MX2018011202A MX2018011202A MX 2018011202 A MX2018011202 A MX 2018011202A MX 2018011202 A MX2018011202 A MX 2018011202A MX 2018011202 A MX2018011202 A MX 2018011202A MX 2018011202 A MX2018011202 A MX 2018011202A
Authority
MX
Mexico
Prior art keywords
vesicles
membrane vesicles
extracellular
therapeutic membrane
therapeutic
Prior art date
Application number
MX2018011202A
Other languages
English (en)
Inventor
Lotvall Jan
Chul Jang Su
Original Assignee
Codiak Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codiak Biosciences Inc filed Critical Codiak Biosciences Inc
Publication of MX2018011202A publication Critical patent/MX2018011202A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)

Abstract

La presente invención se refiere a un método para producir vesículas de membrana a partir de vesículas extracelulares u orgánulos y vesículas de membrana terapéuticas producidas mediante dicho método. La invención también se refiere a vesículas de membrana terapéuticas, un método para tratar un trastorno metabólico mediante el uso de dichas vesículas y dichas vesículas para usar en tratamientos, tales como en el tratamiento de un trastorno metabólico. La invención también se refiere a un método para producir una vesícula de membrana a partir de un orgánulo. Además, la presente invención se refiere a un método para separar una subpoblación de vesículas extracelulares de una masa de vesículas extracelulares.
MX2018011202A 2016-03-15 2017-03-15 Vesiculas de membrana terapeuticas. MX2018011202A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662308805P 2016-03-15 2016-03-15
PCT/US2017/022544 WO2017161010A1 (en) 2016-03-15 2017-03-15 Therapeutic membrane vesicles

Publications (1)

Publication Number Publication Date
MX2018011202A true MX2018011202A (es) 2019-03-28

Family

ID=59852310

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011202A MX2018011202A (es) 2016-03-15 2017-03-15 Vesiculas de membrana terapeuticas.

Country Status (13)

Country Link
US (1) US20200155703A1 (es)
EP (1) EP3430024A4 (es)
JP (1) JP2019513019A (es)
KR (1) KR20180122433A (es)
CN (1) CN109071597A (es)
AU (1) AU2017232498A1 (es)
BR (1) BR112018068746A2 (es)
CA (1) CA3017586A1 (es)
IL (1) IL261490A (es)
MX (1) MX2018011202A (es)
RU (1) RU2018136151A (es)
SG (2) SG10202008883SA (es)
WO (1) WO2017161010A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102706532B1 (ko) 2015-06-10 2024-09-19 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 질환의 치료를 위한 엑소좀의 용도
JP2019536455A (ja) * 2016-11-30 2019-12-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細胞外小胞および方法およびその使用
ES3052812T3 (en) 2017-05-08 2026-01-14 Flagship Pioneering Innovations V Inc Compositions for facilitating membrane fusion and uses thereof
BR112020003354A2 (pt) 2017-08-25 2020-08-18 Codiak Biosciences, Inc. preparação de exossomas terapêuticos usando proteínas de membrana
GB2574785A (en) 2017-09-15 2019-12-25 Jan Loetvall Method and system for identifying membrane proteins on extracellular vesicles
US20190175506A1 (en) 2017-11-17 2019-06-13 Codiak Biosciences, Inc. Loading of Extracellular Vesicles through Imparting of Mechanical Shear
WO2019108957A1 (en) * 2017-12-01 2019-06-06 Alxerion Biotech Corp. Device and system for loaded cellular vesicles and uses thereof
CA3085756A1 (en) 2017-12-14 2019-06-20 Mayo Foundation For Medical Education And Research Purified exosome products, method of making, and methods of using
EP3731849A4 (en) 2017-12-28 2021-12-01 Codiak BioSciences, Inc. EXOSOMES FOR IMMUNO-ONCOLOGY AND ANTI-INFLAMMATORY THERAPY
CN111918967B (zh) * 2018-02-12 2024-11-19 隆萨销售股份公司 用于巨噬细胞极化的方法和组合物
SG11202007606QA (en) 2018-02-17 2020-09-29 Flagship Pioneering Innovations V Inc Compositions and methods for membrane protein delivery
WO2019191429A2 (en) 2018-03-28 2019-10-03 Board Of Regents, The University Of Texas System Identification of epigenetic alterations in dna isolated from exosomes
CN112236131A (zh) 2018-03-29 2021-01-15 技术研究及发展基金有限公司 包含pten抑制剂的囊泡及其用途
US20210024936A1 (en) * 2018-04-09 2021-01-28 Board Of Regents, The University Of Texas System Therapeutic targeting of oncogenes using exosomes
CA3109804A1 (en) 2018-08-16 2020-02-20 The Regents Of The University Of California Chemically and photochemically initiated cell membrane blebbing to induce cell vesicle production, modifications thereof, and uses thereof
SG11202105085QA (en) 2018-11-14 2021-06-29 Flagship Pioneering Innovations V Inc Compositions and methods for compartment-specific cargo delivery
FR3091296B1 (fr) * 2018-12-28 2021-02-19 Univ De Lorraine Systeme fluidique de production de vesicules extracellulaires comprenant un agent therapeutique ou d’imagerie et procede associe
US12397047B2 (en) * 2019-01-09 2025-08-26 Exocure Sweden Ab Bacteria-derived vesicles and uses thereof
CN109913407B (zh) * 2019-02-22 2021-03-23 浙江大学 脂肪来源间充质干细胞类外泌体的制备方法及应用
WO2020207426A1 (zh) * 2019-04-10 2020-10-15 上海交通大学医学院附属上海儿童医学中心 一种体内植入性微孔囊袋及其使用方法和应用
WO2020214542A1 (en) * 2019-04-13 2020-10-22 Flagship Pioneering Innovations Vi, Llc Plant messenger packs encapsulating polypeptides and uses thereof
WO2020252455A1 (en) 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
KR20220070433A (ko) * 2019-08-14 2022-05-31 코디악 바이오사이언시즈, 인크. Stat6을 표적으로 하는 세포외 소포-aso 작제물
KR20220070432A (ko) * 2019-08-14 2022-05-31 코디악 바이오사이언시즈, 인크. Cebp/베타를 표적으로 하는 세포외 소포-aso 작제물
CA3147365A1 (en) * 2019-08-14 2021-02-18 Joanne LIM Extracellular vesicle-nlrp3 antagonist
CN114641570A (zh) * 2019-08-14 2022-06-17 科迪亚克生物科学公司 具有靶向kras的反义寡核苷酸的细胞外囊泡
WO2021030769A1 (en) * 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Extracellular vesicles with nras antisense oligonucleotides
EP4022074A4 (en) * 2019-08-27 2023-11-15 The Trustees of Columbia University in the City of New York Engineered exosomes for targeted delivery
EP4025698A1 (en) 2019-09-03 2022-07-13 Sana Biotechnology, Inc. Cd24-associated particles and related methods and uses thereof
WO2021050975A1 (en) 2019-09-13 2021-03-18 Exocure Biosciences Use of ghost nanovesicles as therapeutics
IT201900024580A1 (it) 2019-12-18 2021-06-18 Consiglio Nazionale Ricerche Vescicole extracellulari da microalghe
EP4099984A4 (en) 2020-02-05 2024-05-01 Diadem Biotherapeutics Inc. ARTIFICIAL SYNAPSES
EP4119166A4 (en) 2020-03-12 2024-06-05 Institute for Basic Science Composition for inducing apoptosis of cells having genomic sequence variation and method for inducing apoptosis of cells by using composition
CN111500607B (zh) * 2020-03-13 2022-05-03 首都医科大学附属北京口腔医院 种植体周围抗炎用融合基因、外泌体、生物涂料以及制备方法和应用
WO2021202604A1 (en) 2020-03-31 2021-10-07 Sana Biotechnology, Inc. Targeted lipid particles and compositions and uses thereof
AU2021310950A1 (en) 2020-07-24 2023-02-16 President And Fellows Of Harvard College Enhanced virus-like particles and methods of use thereof for delivery to cells
EP4228603A4 (en) * 2020-10-16 2024-10-30 University of Delaware CELL MEMBRANE VESICLES AND USES THEREOF
IL305171A (en) * 2021-02-17 2023-10-01 Lonza Sales Ag EXTRACELLULAR VESILE-NLRP3 antagonist
EP4281051A4 (en) * 2021-03-10 2025-06-18 Exocure Sweden AB VESICLES AND USES THEREOF
EP4329783A4 (en) * 2021-04-26 2025-04-02 STRM.Bio Incorporated Compositions and methods related to megakaryocyte-derived extracellular vesicles for fanconi anemia
AU2022280957A1 (en) 2021-05-28 2023-11-30 Sana Biotechnology, Inc. Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses
CN118201625A (zh) * 2021-07-20 2024-06-14 Ags治疗简易股份公司 微藻胞外囊泡、其制备和用途
JP2024528697A (ja) * 2021-07-20 2024-07-30 エイジーエス・セラピューティクス・ソシエテ・パール・アクシオン・サンプリフィエ 微細藻類由来の細胞外小胞、その調製および使用
IT202100027725A1 (it) 2021-10-28 2023-04-28 Torino Politecnico Metodo per l’ottenimento di popolazioni concentrate di vescicole extracellulari lavate del loro carico fisio-patologico
CN118591632A (zh) * 2022-01-27 2024-09-03 国家纳米科学中心 细菌外膜囊泡来源的核酸纳米疫苗及其应用
WO2023144127A1 (en) 2022-01-31 2023-08-03 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
WO2023178500A1 (en) * 2022-03-22 2023-09-28 Beijing Theraxyte Bioscience Co. Ltd. Therapeutic vesicles and methods of processing the same
WO2023232976A1 (en) 2022-06-03 2023-12-07 Ags Therapeutics Sas Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
CN114908046B (zh) * 2022-06-16 2024-01-02 四川大学 一种线粒体膜囊泡的制备方法
US20260055146A1 (en) 2022-08-24 2026-02-26 Sana Biotechnology, Inc. Delivery of heterologous proteins
EP4587064A1 (en) * 2022-09-14 2025-07-23 Mayo Foundation for Medical Education and Research Methods and materials for treating cancer
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
JP7371975B1 (ja) 2022-09-27 2023-10-31 セルソース株式会社 細胞外小胞の製造方法及び細胞外小胞含有組成物
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
CN121038801A (zh) 2022-10-24 2025-11-28 Ags治疗简易股份公司 来自微藻的细胞外囊泡、它们在鼻内施用时的生物分布及其用途
WO2024194423A1 (en) * 2023-03-23 2024-09-26 Ags Therapeutics Sas Extracellular vesicles from microalgae, their use for vaccines and for immunomodulation
CN118207158B (zh) * 2023-06-21 2024-08-27 天津医科大学眼科医院 一种细胞内来源的纳米囊泡的制备方法及应用
CN119570732A (zh) * 2023-09-05 2025-03-07 中国科学院基础医学与肿瘤研究所(筹) 胞质体囊泡的制备方法及其应用
WO2025067018A1 (zh) * 2023-09-26 2025-04-03 天津医科大学眼科医院 一种来源于细胞内的靶向纳米囊泡的制备方法和应用
WO2025176843A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0416120D0 (en) * 2004-07-19 2004-08-18 Health Prot Agency Stable compositions containing OMV's
US9085778B2 (en) * 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
WO2009130649A2 (en) * 2008-04-21 2009-10-29 Nanoxis Ab Plasma membrane vesicles and methods of making and using same
US20130273544A1 (en) * 2012-04-17 2013-10-17 Life Technologies Corporation Methods and compositions for exosome isolation
CA2936100A1 (en) * 2013-12-04 2015-06-11 Board Of Regents, The University Of Texas System Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis
AU2014361826A1 (en) * 2013-12-12 2016-06-23 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for targeting disorders and diseases using particle delivery components

Also Published As

Publication number Publication date
WO2017161010A1 (en) 2017-09-21
SG11201807401RA (en) 2018-09-27
KR20180122433A (ko) 2018-11-12
RU2018136151A (ru) 2020-04-15
IL261490A (en) 2018-10-31
EP3430024A1 (en) 2019-01-23
EP3430024A4 (en) 2019-11-13
US20200155703A1 (en) 2020-05-21
RU2018136151A3 (es) 2020-08-03
BR112018068746A2 (pt) 2019-01-22
CN109071597A (zh) 2018-12-21
AU2017232498A1 (en) 2018-10-18
JP2019513019A (ja) 2019-05-23
SG10202008883SA (en) 2020-10-29
CA3017586A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
MX2018011202A (es) Vesiculas de membrana terapeuticas.
PH12020550169A1 (en) Isothiocyanate containing brassicaceae products and method of preparation thereof
ZA201804513B (en) Method of treating c3 glomerulopathy
NZ742327A (en) Neural cell extracellular vessicles
EP4417252A3 (en) Cannabis based therapeutic and method of use
PH12014502010A1 (en) Bispecific antibodies against human tweak and human il17 and uses thereof
NZ737796A (en) Anti-tau antibodies and methods of use
MY175308A (en) Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
MY179105A (en) Methods of treating alzheimer's disease
PH12017501035A1 (en) Method for the production of a pharmaceutical delivery system
EA033335B1 (ru) Антитело к интерлейкину-21 и его применение для лечения аутоиммунного состояния
PH12016502150A1 (en) Method for treating renal cell carcimona
EP3263119A4 (en) Composition including extracellular vesicles derived from bacteria of bacillus sp. for treating pregnancy-associated diseases
AU2018337076A1 (en) Method of treatment
WO2018088694A3 (ko) 인위적으로 조작된 sc 기능 조절 시스템
PH12017501872A1 (en) Methods of treating diseases
MX2019000677A (es) Células miméticas de células b.
SG10201804034QA (en) Methods for treating hypotension
EP4480577A3 (en) Structured elements and methods of use
HK1257882A1 (zh) 通过t细胞疗法来治疗多发性骨髓瘤和浆细胞性白血病的方法
EA201790360A1 (ru) Получение полностью процессированного и функционального фактора x в фурин-секретирующей системе экспрессии млекопитающего
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
WO2015034967A3 (en) Hyperoxic therapy systems, methods and apparatus
MX2016015574A (es) Composiciones esterilizadas de las proteinas ivig y kh para modular los linfocitos y tratar el virus de la hepatitis b.
MX2017004842A (es) Levosimendan para uso en el tratamiento de enfermedades de las neuronas motoras (por ejemplo esclerosis lateral amiotrofica).